Literature DB >> 21461918

Cell therapeutic options in liver diseases: cell types, medical devices and regulatory issues.

Andreas K Nussler1, Katrin Zeilinger, Lilianna Schyschka, Sabrina Ehnert, Jörg C Gerlach, Xueying Yan, Serene M L Lee, Maren Ilowski, Wolfgang E Thasler, Thomas S Weiss.   

Abstract

Although significant progress has been made in the field of orthotopic liver transplantation, cell-based therapies seem to be a promising alternative to whole-organ transplantation. The reasons are manifold but organ shortage is the main cause for this approach. However, many problems such as the question which cell type should be used or which application site is best for transplantation have been raised. In addition, some clinicians have had success by cultivating liver cells in bioreactors for temporary life support. Besides answering the question which cell type, which injection site or even which culture form should be used for liver support recent international harmonization of legal requirements is needed to be addressed by clinicians, scientists and companies dealing with cellular therapies. We here briefly summarize the possible cell types used to partially or temporarily correct liver diseases, the most recent development of bioreactor technology and important regulatory issues.

Entities:  

Mesh:

Year:  2011        PMID: 21461918     DOI: 10.1007/s10856-011-4306-7

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  147 in total

1.  Three-dimensional co-culture of primary human liver cells in bioreactors for in vitro drug studies: effects of the initial cell quality on the long-term maintenance of hepatocyte-specific functions.

Authors:  Katrin Zeilinger; Igor M Sauer; Gesine Pless; Catrin Strobel; Jeannette Rudzitis; Aiguo Wang; Andres K Nüssler; Alexander Grebe; Lei Mao; Stefan H G Auth; Juliane Unger; Peter Neuhaus; Jörg C Gerlach
Journal:  Altern Lab Anim       Date:  2002 Sep-Oct       Impact factor: 1.303

Review 2.  Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review.

Authors:  Lise L Kjaergard; Jianping Liu; Bodil Als-Nielsen; Christian Gluud
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

3.  Efficient differentiation of human embryonic stem cells to definitive endoderm.

Authors:  Kevin A D'Amour; Alan D Agulnick; Susan Eliazer; Olivia G Kelly; Evert Kroon; Emmanuel E Baetge
Journal:  Nat Biotechnol       Date:  2005-10-28       Impact factor: 54.908

4.  Slow continuous ultrafiltration with bound solute dialysis.

Authors:  John F Patzer; Stefan A Safta; Richard H Miller
Journal:  ASAIO J       Date:  2006 Jan-Feb       Impact factor: 2.872

5.  Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up.

Authors:  Etienne M Sokal; Françoise Smets; Annick Bourgois; Lionel Van Maldergem; Jean-Paul Buts; Raymond Reding; Jean Bernard Otte; Veerle Evrard; Dominique Latinne; Marie Françoise Vincent; Anne Moser; Humberto E Soriano
Journal:  Transplantation       Date:  2003-08-27       Impact factor: 4.939

6.  One liver for four children: first clinical series of liver cell transplantation for severe neonatal urea cycle defects.

Authors:  Jochen Meyburg; Anibh M Das; Friederike Hoerster; Martin Lindner; Heinz Kriegbaum; Guido Engelmann; Jan Schmidt; Michael Ott; Andrea Pettenazzo; Thomas Luecke; Harald Bertram; Georg F Hoffmann; Alberto Burlina
Journal:  Transplantation       Date:  2009-03-15       Impact factor: 4.939

7.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

8.  In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state.

Authors:  Marius Wernig; Alexander Meissner; Ruth Foreman; Tobias Brambrink; Manching Ku; Konrad Hochedlinger; Bradley E Bernstein; Rudolf Jaenisch
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

9.  Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts.

Authors:  Masato Nakagawa; Michiyo Koyanagi; Koji Tanabe; Kazutoshi Takahashi; Tomoko Ichisaka; Takashi Aoi; Keisuke Okita; Yuji Mochiduki; Nanako Takizawa; Shinya Yamanaka
Journal:  Nat Biotechnol       Date:  2007-11-30       Impact factor: 54.908

10.  Human hepatic stem cells from fetal and postnatal donors.

Authors:  Eva Schmelzer; Lili Zhang; Andrew Bruce; Eliane Wauthier; John Ludlow; Hsin-lei Yao; Nicholas Moss; Alaa Melhem; Randall McClelland; William Turner; Michael Kulik; Sonya Sherwood; Tommi Tallheden; Nancy Cheng; Mark E Furth; Lola M Reid
Journal:  J Exp Med       Date:  2007-07-30       Impact factor: 14.307

View more
  1 in total

1.  New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.

Authors:  Jennifer R Ferrer; Attasit Chokechanachaisakul; Jason A Wertheim
Journal:  Curr Transplant Rep       Date:  2015-06-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.